Weight-Loss drug may change how birth control works in some women
NCT ID NCT07523711
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 4 times
Summary
This early-stage study looks at how a new weight-loss drug, maridebart cafraglutide, changes the way the body processes oral contraceptives. It involves 45 postmenopausal women aged 45 to 65 who are overweight or obese. The goal is to see if the drug affects birth control hormone levels, which could impact how well the pill works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, 75247-4968, United States
-
Fortrea Clinical Research Unit Inc. - Madison
Madison, Wisconsin, 53704-2526, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- A daily pill for obesity? zenagamtide faces its biggest test yet.
- Dance and walking may boost heart health in obesity — a trial puts it to the test